Single-Use Spherical Pulsed Ablation Catheter for Paroxysmal Atrial Fibrillation
2026년 9월 3일 업데이트: Shanghai Shineyo Medical Co., Ltd.
A Prospective, Multicenter, Randomized Controlled, Non-inferiority Clinical Trial Evaluating the Safety and Efficacy of Cardiac Pulsed Field Ablation Devices Combined With Single-use Spherical Pulsed Ablation Catheters in Treating Paroxysmal Atrial Fibrillation
The goal of this clinical trial is to learn if the cardiac pulsed field ablation system, composed of the cardiac pulsed field ablation device, the single-use spherical pulsed ablation catheter, and the optional cardiac three-dimensional mapping system, works to treat symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation. It will also learn about the safety of this set of investigational medical devices. The main questions it aims to answer are:
Does the combination of the cardiac pulsed field ablation device and the single-use spherical pulsed ablation catheter improve the 12-month post-procedure treatment success rate for participants with paroxysmal atrial fibrillation? What adverse events and medical problems do participants experience after receiving the investigational pulsed field ablation treatment? Researchers will compare the investigational pulsed field ablation therapy to the clinically recognized radiofrequency ablation therapy using the marketed Diagnostic/Ablation Deflectable Tip Catheter to verify the non-inferior effectiveness and safety of the test devices for treating paroxysmal atrial fibrillation.
Participants will:
Undergo screening assessments within 14 days before the procedure, including signing informed consent, completing medical history collection, physical vital sign checks, laboratory tests, 12-lead ECG, echocardiogram, baseline quality of life score evaluation, and confirmation of meeting all inclusion criteria without any exclusion criteria Be randomly assigned to either the investigational pulsed field ablation group or the control radiofrequency ablation group on the day of surgery Receive the assigned ablation procedure, with intra-operative recordings of core surgical parameters, pain score assessment, and investigational device performance evaluation Complete post-procedure assessments before discharge (within 7 days after surgery), including post-operative laboratory tests, pain follow-up, and recording of re-ablation, electrical cardioversion, readmission events, adverse events and concomitant medications Return for follow-up visits or complete telephone follow-ups at 1 month (±7 days), 3 months (±15 days), 6 months (±30 days) and 12 months (±30 days) after the procedure, which include physical vital sign checks, remote ECG monitoring (daily for the first 3 months after surgery, weekly from month 4 to month 12, and as needed when symptoms occur), 72-hour Holter and 12-lead ECG tests at the 6-month and 12-month visits, echocardiogram reexamination, repeated quality of life scoring, and continuous recording of arrhythmia recurrence, subsequent treatment events, adverse events and medication status Keep a symptom and ECG monitoring diary for the entire 12-month follow-up period after the procedure, as required by the trial protocol
연구 개요
상태
아직 모집하지 않음
정황
연구 유형
중재적
등록 (추정된)
284
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Shuang Pan
- 전화번호: 86-18621903981
- 이메일: panshuang@shineyomedical.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Age ≥18 years and ≤75 years, without gender restriction
- Patients with symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation
- Subjects scheduled for atrial fibrillation catheter ablation
- Subjects who agree to participate in this study and voluntarily sign the informed consent form
Exclusion Criteria:
- Persistent atrial fibrillation, or atrial fibrillation secondary to electrolyte disturbance, thyroid disease, alcohol or other reversible/non-cardiac causes
- Anterior-posterior left atrial diameter (measured by MRI, CT or TTE) ≥55 mm
- Prior history of any atrial surgery or atrial endocardial/epicardial ablation, except cavotricuspid isthmus ablation or right-sided supraventricular tachycardia ablation
- Existing left atrial thrombus, atrial myxoma, atrial septal patch or shunt device
- Prior or planned concomitant left atrial appendage closure procedure at index procedure
- Diagnosis of hypertrophic cardiomyopathy
- History of congenital heart disease with residual anatomical or conduction abnormalities
- Hemodynamically significant valvular heart disease judged by investigator to be ineligible for enrollment
- Prior valve repair or valve replacement surgery
- Implanted pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy device
- NYHA functional class Ⅲ-Ⅳ
- Left ventricular ejection fraction (LVEF) ≤40%
- Symptomatic hypotension or uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg in two baseline measurements)
- Symptomatic resting bradycardia or type-second-degree or third-degree atrioventricular block
- Contraindication to systemic anticoagulation, or unwillingness to receive systemic anticoagulation
- Medical conditions that may interfere with study participation, assessment or treatment, significantly increase study-related risk, or alter study outcomes, including but not limited to: moderate-to-severe COPD, moderate-to-severe pulmonary hypertension, or diseases causing severe dyspnea or resting hypoxemia; renal insufficiency (eGFR<30 ml/min/1.73 m²) or history of hemodialysis or renal transplantation; active malignancy or treated malignancy within 24 months prior to enrollment (excluding basal cell or squamous cell skin carcinoma); active systemic infection
- Myocardial infarction, unstable angina, heart failure hospitalization within 3 months prior to enrollment; any cardiac interventional or open-heart surgery within 1 month prior to enrollment (coronary angiography excluded)
- Stroke (excluding silent stroke), transient ischemic attack or any thromboembolic event within 3 months prior to enrollment
- Expected survival less than 1 year
- Female subjects who are pregnant, lactating, or planning pregnancy during study period
- Participation in another interventional device clinical trial within 1 month before enrollment, or within 5 half-lives of last study drug for drug clinical trials
- Any other condition judged by investigator to make the subject unsuitable for this clinical trial
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Investigational Cardiac Pulsed Field Ablation (PFA) Arm
Intervention group receiving cardiac pulsed field ablation for paroxysmal atrial fibrillation
|
It consists of a cardiac pulsed electric field ablation apparatus and a single-use spherical pulsed ablation catheter, which can be paired with an optional cardiac three-dimensional mapping system to complete pulsed electric field ablation in the pulmonary vein antrum region, achieve pulmonary vein electrical isolation, and is indicated for the treatment of symptomatic, recurrent, drug-refractory paroxysmal atrial fibrillation.
|
|
활성 비교기: Control Radiofrequency (RF) Catheter Ablation Arm
Control group receiving conventional radiofrequency catheter ablation for paroxysmal atrial fibrillation
|
Using the commercially available diagnostic/ablation steerable-tip catheter in combination with a conventional clinical radiofrequency ablation device, point-by-point radiofrequency ablation is performed on the pulmonary vein antrum to achieve pulmonary vein electrical isolation.
This is the current standard clinical treatment for paroxysmal atrial fibrillation.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants with freedom from atrial fibrillation at 12 months post-index ablation (90-day post-procedure blanking period)
기간: 12 months post-index ablation
|
Treatment success at 12 months post-index ablation is defined as no amiodarone use and no repeat ablation during the 3-month post-procedure blanking period, except repeat ablation for CTI-dependent atrial flutter.
Following the end of the blanking period (i.e., 3 months to 12 months after the procedure), subjects shall have no use of Class I/III antiarrhythmic drugs, no repeat ablation, no electrical cardioversion (interventions for CTI-dependent atrial flutter excluded), and no episodes of atrial fibrillation, atrial flutter, or atrial tachycardia lasting ≥30 seconds confirmed by electrocardiogram or Holter monitoring (CTI-dependent atrial flutter excluded).
|
12 months post-index ablation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of participants with treatment success at 12 months post-index ablation
기간: From the end of 30-day post-procedure blanking period to 12 months after the index ablation
|
From the end of 30-day post-procedure blanking period to 12 months after the index ablation
|
|
|
Acute procedural success rate on the day of index ablation
기간: On the day of index ablation (intra-procedure completion)
|
On the day of index ablation (intra-procedure completion)
|
|
|
Atrial fibrillation burden assessed by 72-hour Holter monitoring
기간: 6-month and 12-month follow-up; daily monitoring 1-3 months post-procedure, weekly monitoring 4-12 months post-procedure, additionally upon symptom occurrence
|
6-month and 12-month follow-up; daily monitoring 1-3 months post-procedure, weekly monitoring 4-12 months post-procedure, additionally upon symptom occurrence
|
|
|
Pain score at 2-hours and 24-hours after index ablation
기간: 2 hours after recovery from anesthesia; 24 hours post-index ablation
|
2 hours after recovery from anesthesia; 24 hours post-index ablation
|
|
|
Recurrence rate of early atrial tachyarrhythmias (atrial fibrillation / atrial flutter / atrial tachycardia)
기간: 1-month and 3-month post-index ablation
|
1-month and 3-month post-index ablation
|
|
|
Proportion of participants receiving electrical cardioversion, repeat ablation, emergency department visit or hospitalization due to documented recurrent atrial arrhythmia
기간: Prior to hospital discharge, 1-month, 3-month, 6-month, 12-month post-index ablation
|
Prior to hospital discharge, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Proportion of participants with re-initiation of antiarrhythmic drugs
기간: 1-month, 3-month, 6-month, 12-month post-index ablation
|
1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Time from index ablation to first documented recurrence of atrial fibrillation, atrial flutter or atrial tachycardia
기간: Up to 12-month post-index ablation, assessed at 1-,3-,6-,12-month visits
|
Up to 12-month post-index ablation, assessed at 1-,3-,6-,12-month visits
|
|
|
Symptom-free survival of participants
기간: 1-month, 3-month, 6-month, 12-month post-index ablation
|
1-month, 3-month, 6-month, 12-month post-index ablation
|
|
|
Change in Atrial Fibrillation Effect on Quality-of-Life (AFEQT) total score from baseline
기간: Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
The change from baseline in the total score of the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire.
Measurement tool: AFEQT questionnaire.
Unit: score.
|
Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
Performance evaluation of investigational device
기간: On the day of index ablation
|
On the day of index ablation
|
|
|
Incidence of major adverse events
기간: Within 7 days post-index ablation and up to 12 months post-index ablation
|
Within 7 days post-index ablation and up to 12 months post-index ablation
|
|
|
Incidence of device- or procedure-related stroke or transient ischemic attack (TIA)
기간: Through study completion, average of 12-month follow-up
|
Number of subjects experiencing device- or procedure-related stroke or transient ischemic attack (TIA).
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Incidence of device- related serious adverse events (SAE)
기간: Through study completion, average of 12-month follow-up
|
Number of device-related serious adverse events divided by the total number of serious adverse events that occurred during follow-up.
Measurement tool: clinical adverse-event reporting.
Unit: percentage of SAE events.
|
Through study completion, average of 12-month follow-up
|
|
Laboratory values of myocardial injury biomarkers
기간: Within 48-hours post-index ablation
|
Laboratory values of myocardial injury biomarkers collected within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: laboratory value.
|
Within 48-hours post-index ablation
|
|
Incidence of hemolysis-associated renal injury
기간: Within 48-hours post-index ablation
|
Number of subjects with hemolysis-associated renal injury occurring within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: percentage of subjects.
|
Within 48-hours post-index ablation
|
|
Incidence of other adverse events (AE)
기간: Through study completion, average of 12-month follow-up
|
Number of subjects experiencing other adverse events (AEs) throughout the study period.
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Total index ablation procedure duration
기간: Periprocedural
|
Total time duration of the index ablation procedure.
Unit: minutes.
|
Periprocedural
|
|
Left-atrial device dwell time during index ablation
기간: Periprocedural
|
Total dwell time of investigational device within left atrium during index ablation.
Unit: minutes.
|
Periprocedural
|
|
Pulmonary vein isolation (PVI) procedural time
기간: Intra-procedural
|
Time spent for pulmonary vein isolation (PVI) manipulation during index ablation.
Unit: minutes.
|
Intra-procedural
|
|
Total fluoroscopy time during index ablation
기간: Intra-procedural
|
Total fluoroscopy exposure time during index ablation.
Unit: minutes.
|
Intra-procedural
|
|
Total contrast media volume administered
기간: Intra-procedural
|
Total volume of contrast media used during index ablation.
Unit: mL.
|
Intra-procedural
|
|
Number of ablation energy deliveries
기간: Intra-procedural
|
Total count of ablation energy deliveries applied during index ablation.
Unit: number of subjects (count).
|
Intra-procedural
|
|
Incidence of other serious adverse events (SAE) throughout the study period
기간: Through study completion, average of 12-month follow-up
|
Number of subjects with other serious adverse events occurring during the entire study period.
Measurement tool: serious adverse-event reporting.
Unit: percentage of subjects.
|
Through study completion, average of 12-month follow-up
|
|
Laboratory values of inflammatory biomarkers
기간: Within 48-hours post-index ablation
|
Laboratory values of inflammatory biomarkers collected within 48-hours post-index ablation or prior to hospital discharge, whichever comes first.
Unit: laboratory value.
|
Within 48-hours post-index ablation
|
|
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility score from baseline
기간: Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
The change from baseline in the utility index score calculated from the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire.
Measurement tool: EQ-5D-5L questionnaire.
Unit: index score.
|
Baseline, 1-month, 3-month, 6-month, 12-month post-index ablation
|
|
Proportion of procedure-related serious adverse events (SAEs) among all SAEs
기간: Through study completion, average of 12-month follow-up
|
Number of procedure-related serious adverse events divided by the total number of serious adverse events that occurred during follow-up.
Measurement tool: clinical adverse-event reporting.
Unit: percentage of SAE events.
|
Through study completion, average of 12-month follow-up
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 9월 1일
기본 완료 (추정된)
2028년 3월 1일
연구 완료 (추정된)
2028년 6월 1일
연구 등록 날짜
최초 제출
2026년 8월 20일
QC 기준을 충족하는 최초 제출
2026년 9월 3일
처음 게시됨 (실제)
2026년 9월 10일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 9월 10일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 9월 3일
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- (2026)-(289)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
IPD 계획 설명
Individual-participant-level data will not be shared with other researchers.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
미국에서 제조되어 미국에서 수출되는 제품
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .